Invitation for presentation of Sedana Medical’s fourth quarter and Year-End Report 2021
Non-regulatory
Sedana Medical AB (publ) plans to present its fourth quarter and Year-End Report for 2021 in an audiocast on February 17 at 13.30 CET.
Sedana Medical’s Sedaconda ACD recommended by NICE
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the National Institute for Health and Care Excellence (NICE) has issued positive guidance recommending Sedaconda ACD as a cost-saving option for delivering inhaled sedation in inten…
Sedana Medical appoints Johan Spetz as new CFO
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces the appointment of Johan Spetz as the company’s new Chief Financial Officer (CFO). Johan Spetz will take office no later than April 4, 2022, succeeding Susanne Andersson who will leave h…
Sedana Medical receives IND approval for US trials
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to initiate phase III pivotal clinical trials with its Sedaconda pro…
Sedana Medical applies for market approval in Italy
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has submitted an application for market approval for Sedaconda (isoflurane) for inhaled sedation in intensive care in Italy.
Sedana Medical has carried out a directed share issue raising gross proceeds of 615 MSEK
Regulatory
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, CANADA, NEW ZEALAND, JAPAN, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DI…
Sedana Medical announces intention to carry out a directed share issue of approximately 600 MSEK
Regulatory
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, CANADA, NEW ZEALAND, JAPAN, SINGAPORE OR SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH THE DI…
Sedana Medical submits IND for US clinical trials
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA), with the aim to commence its phase III pivotal clinical trials…
Sedana Medical AB (publ), Third Quarter Report 2021
Regulatory
Sedaconda (isoflurane) approved in 11 European markets
Sedana Medical’s Nomination committee appointed
Regulatory
Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 10, 2021, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes t…
Invitation for presentation of Sedana Medical’s interim report for the third quarter 2021
Non-regulatory
Sedana Medical AB (publ) plans to present its interim report for the third quarter 2021 in an audiocast on November 4 at 13.30 CET.
Sedana Medical presents at ESICM
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that the company will hold a scientific symposium at ESICM Lives 2021, the annual congress of the European Society of Intensive Care Medicine. Additional data on inhaled sedation will al…
Sedana Medical receives approval in Germany
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has received market approval for inhaled sedation in Germany.
Sedana Medical presenting at ISICEM
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company will host a symposium at the International Symposium on Intensive Care and Emergency Medicine (ISICEM) in Brussels on August 31-September 3, 2021, where the full details…
Sedana Medical's Sedaconda study published in the Lancet
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the results of the company's pivotal study Sedaconda (SED001) have been published in the highly ranked scientific journal, the Lancet Respiratory Medicine.
Sedana Medical receives approval in France
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has received market approval for inhaled sedation in France.
Invitation for presentation of Sedana Medical’s interim report for the second quarter 2021
Non-regulatory
Sedana Medical AB will present its interim report for the second quarter 2021 in an audiocast on August 19 at 13.30 CEST.
Sedana Medical receives approval for European dossier
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has received a positive outcome for its European registration application for the drug Sedaconda (isoflurane) for inhaled sedation. Sedaconda is indicated for sedation o…
Sedana Medical announces positive FDA interaction
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has completed a successful End of phase II meeting with the US Food and Drug Administration (FDA). The FDA accepted Sedana Medical's proposals for phase III program, inc…